DEVELOPMENT AND LICENSE AGREEMENT between TEVA PHARMACEUTICALS USA, INC. (“Teva”) and BIOSANTE PHARMACEUTICALS, INC. (“BioSante”)Development and License Agreement • November 8th, 2012 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Pennsylvania
WHEREAS, BioSante is engaged in the development of pharmaceutical products and has in development the pharmaceutical product listed in Annex A hereto (the “Product” as defined further below);
FIRST AMENDMENT TO DEVELOPMENT AND LICENSE AGREEMENT (“First Amendment”) between TEVA PHARMACEUTICALS USA, INC. (“Teva”) and BIOSANTE PHARMACEUTICALS, INC. (“BioSante”)Development and License Agreement • November 8th, 2012 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances)
WHEREAS, Teva and BioSante entered into a Development and License Agreement with an effective date of December 27, 2002 (“the Agreement”);
THIRD AMENDMENT TO DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • November 8th, 2012 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Pennsylvania
THIS AMENDMENT TO DEVELOPMENT AND LICENSE AGREEMENT (“Third Amendment”), is entered into as of the Third Amendment Effective Date (as defined below), by and between Teva Pharmaceuticals USA, Inc. (“Teva”) and BioSante Pharmaceuticals, Inc. (“BioSante”), and amends certain terms of the Agreement (as defined below).
